Please assess the completion status of the following clinical trial:

Trial Title: Study of Pimecrolimus Treatment for Atopic Dermatitis of African American Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* African American children aged 2 to 17 years~* mild to moderate atopic dermatitis~Exclusion Criteria:~* m-EASI less than 3 at baseline~* allergy to Elidel or components~* use of oral steroids, immunosuppressive agents,cytostatics of phototherapy within 4 weeks prior to study.~* previous continuous or non-continuous use of pimecrolimus or tacrolimus for greater than 11 months within 2 weeks of enrollment.~* active skin infections.~* immunocompromised patients.~* previous history of skin cancer or lymphoma~* any hypopigmentation in study areas~* pregnant or breastfeeding~* participation in another investigational trial

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Pimecrolimus (Type: EXPERIMENTAL): Pimecrolimus 1% cream
- 2 (Type: PLACEBO_COMPARATOR): Placebo cream over affected study area

Based on this trial design, predict the completion outcome and termination type (if applicable).